These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12746614)

  • 21. Insulin resistance syndrome. Description, pathogenesis, and management.
    Miller JL
    Postgrad Med; 2003 May; Spec No():27-34. PubMed ID: 12785129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Metabolic syndrome from the point of view of a cardiologist: diagnosis, non drug and drug treatment].
    Makolkin VI; Podzolkov VI; Napalkov DA
    Kardiologiia; 2002; 42(12):91-7. PubMed ID: 12494026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
    Bouskela E; Kraemer de Aguiar LG; Nivoit P; Bahia LR; Villela NR; Bottino DA
    Bull Acad Natl Med; 2007 Mar; 191(3):475-92; discussion 492-3. PubMed ID: 18072649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
    Mayer SB; Evans WS; Nestler JE
    Womens Health (Lond); 2015 Mar; 11(2):137-49. PubMed ID: 25776288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
    Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
    JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology and long-term management of the metabolic syndrome.
    Pi-Sunyer FX
    Obes Res; 2004 Dec; 12 Suppl():174S-80S. PubMed ID: 15687414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.
    Dandona P; Aljada A; Chaudhuri A; Mohanty P; Garg R
    Circulation; 2005 Mar; 111(11):1448-54. PubMed ID: 15781756
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic syndrome.
    Reaven P
    J Insur Med; 2004; 36(2):132-42. PubMed ID: 15301226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
    Franks S
    Clin Endocrinol (Oxf); 2011 Feb; 74(2):148-51. PubMed ID: 21121941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the metabolic syndrome.
    Grant RW; Meigs JB
    Panminerva Med; 2005 Dec; 47(4):219-28. PubMed ID: 16489321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome, diet and exercise.
    De Sousa SM; Norman RJ
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():140-151. PubMed ID: 26972165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Insulin resistance in type 2 diabetes patients].
    Chodorowski Z; Sein Anand J; Cylkowska B; Hajduk A; Kujawska-Danecka H
    Przegl Lek; 2007; 64(4-5):368-9. PubMed ID: 17724917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of metformin in abdominal obesity].
    Mkrtumian AM; Markova TN; Kichigin VA; Podachina SV; Zhuchkova SM
    Ter Arkh; 2014; 86(8):80-4. PubMed ID: 25306749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic syndrome: a gathering challenge in a time of abundance.
    Bricker LA; Greydanus DE
    Adolesc Med State Art Rev; 2008 Dec; 19(3):475-97, ix. PubMed ID: 19227387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
    Schindler C
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):7-26. PubMed ID: 19124392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].
    Vanuzzo D; Pilotto L; Mirolo R; Pirelli S
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):6S-17S. PubMed ID: 18773746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome and new category 'pre-hypertension' in a Japanese population.
    Kanauchi M; Kanauchi K; Hashimoto T; Saito Y
    Curr Med Res Opin; 2004 Sep; 20(9):1365-70. PubMed ID: 15383184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.